Diamond Therapeutics Announces Health Canada Approval of Clinical Trial with Low-Dose Psilocybin
TORONTO, Aug. 17, 2021 /PRNewswire/ – Diamond Therapeutics Inc. (“Diamond”), a drug development company focused on low-dose psychedelic therapies for use in the treatment of mental health, is pleased to announce that it has received a No Objection Letter from Health Canada, allowing…
Comments Off on Diamond Therapeutics Announces Health Canada Approval of Clinical Trial with Low-Dose Psilocybin